https://vitasmlab.net

TAUIMARK

Tau Aggregation Inhibitors Targeted Library

Abnormal aggregation of the tau protein into neurofibrillary tangles is a direct driver of neuronal death and cognitive decline in Alzheimer's disease and related tauopathies. These toxic aggregates disrupt cellular transport, impair synaptic function, and propagate pathology throughout the brain, correlating strongly with disease severity. Existing therapies offer only symp- tomatic relief and do not halt disease progression. The search for small molecules that could selectively inhibit tau aggrega- tion or promote the disassembly of existing tangles represent a critical strategy for disease-modifying treatment. Developing such inhibitors is paramount to preventing the spread of neurodegeneration, preserving cognitive function, and addressing the root cause of these devastating disorders. Effective tau aggregation inhibitors could significantly slow or stop the progression of Alzheimer's and other tauopathies, fulfilling a massive unmet medical need for millions of patients worldwide.





STK179855 STK901446 STL114614

The Tau Aggregation Inhibitors Targeted Library (TAUIMARK) is a collection of 1000 rule-of-five compliant compounds specifically designed to potentially inhibit aggregation of tau protein. Each compound was selected based on structural similarity to known potential effectors. TAUIMARK provides a robust foundation for high-throughput screening, offering a diverse array of chemical starting points for discovering new effectors with potential to augment tau aggregation.

Distribution of Parameters



If you have any specific needs for your project, we can provide specially tailored compound library based on your request.

Have questions or need a quote? Contact Irina Haywood (Ryabushenko) at
irina@vitasmlab.biz
Let's Connect on LinkedIn! Expand your professional network.

We look forward to collaborating with you!
Empowering Your Research, One Molecule at a Time.